Cantor Fitzgerald Reiterates Overweight on Disc Medicine, Maintains $170 Price Target

Benzinga · 2d ago
Cantor Fitzgerald analyst Kristen Kluska reiterates Disc Medicine (NASDAQ:IRON) with a Overweight and maintains $170 price target.